The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
T cell antigen coupler (TAC) therapy - TAC01-CD19 - granted Fast Track designation by the FDA for the treatment of patients with R/R DLBCL
On the 7th of November 2019, TAC01-CD19 was granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for use in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after at least 2 prior systemic therapies.1
TAC01-CD19 is a T cell antigen coupler (TAC) that is distinct from chimeric antigen receptor T cells (CAR-T). This TAC receptor product employs patient-derived genetically engineered T cells to target CD19, a B-cell marker expressed on the surface of B-cell tumors, independent of the Major Histocompatibility Complex.2 Preclinical data indicate that TAC01-CD19 could be highly efficacious without treatment-associated toxicity in animal models of CD19-positive B-cell malignancies.3
A phase I/II study (TACTIC-19) NCT03880279 evaluating the efficacy and safety of TAC01-CD19 in patients with CD19-positive B-cell malignancies including DLBCL is anticipated to start by the end of 2019.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content